Jane Fisken
Jan Rutherford



Presents a study that assessed the evolution of biotechnology company business models in relation to investment trends in the European public and private markets and the biotechnology industry, as of December 2001. Review of various aspects of several business models; Discussion on investment trends in public markets; Outlook for biotechnology business models.

Keywords:business model ,product ,platform ,hybrid ,value generation ,investment trend ,Europe ,relationship ,management ,en ,